Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tandem Diabetes Care (TNDM)

Tandem Diabetes names Jean-Claude Kyrillos executive VP and chief operating officer

Neutral Impact 3 of 5 leadership Written later

Tandem Diabetes Care appointed Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. He previously held president and general manager roles at Envista Holdings, Qualcomm Life, Becton Dickinson and ResMed, according to the filing. The filing sets his base salary at $450,203.73 and a target annual bonus of 60% of base salary, and it includes change-of-control severance terms.

Key points

  • Appointment effective June 21, 2024; the Board approved it on June 19, 2024
  • Offer letter dated June 10, 2024 sets base salary of $450,203.73
  • Target annual bonus of 60% of base salary; target long-term incentive award of 400% of base salary in RSUs
  • Prior role: President of Diagnostics and Digital Solutions at Envista Holdings, February 2020 to June 2023

The filing

CompanyTandem Diabetes Care (TNDM)
Form8-K, current report
Filed with the SECJun 21, 2024, 4:19 PM ET
Accession number0001438133-24-000166

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 21, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.